Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.

尽管在前列腺癌的筛查和治疗方面取得了进展，但可用的治疗选择，特别是对于疾病的后期阶段，仍然有限，而且难治性设置代表了严重的未满足的医疗需求。此外，疾病的异质性和患者获得医疗进步的差异导致患者之间的结果存在相当大的差异。基于基因组测序的疾病分类是一种很有前途的方法，可用于识别肿瘤表现出可操作靶点的患者并做出更明智的治疗决策。在这里，我们讨论了如何加速精准肿瘤学，为晚期前列腺癌患者提供更广泛的基因组驱动的临床决策，为药物开发提供信息，并最终为新的治疗模式做出贡献。